Drug Profile
Rulonilimab - Shandong New age Pharmaceutical
Alternative Names: Anti PD-1 monoclonal antibody - Shandong New Age Pharmaceutical; Anti-programmed cell death-1 monoclonal antibody - Shandong New Age Pharmaceutical; F-520; Recombinant humanized anti-PD-1 monoclonal antibodyLatest Information Update: 01 Feb 2024
Price :
$50
*
At a glance
- Originator Shandong New age Pharmaceutical
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Liver cancer
- Phase II Cervical cancer; Solid tumours
- No development reported Lymphoma
Most Recent Events
- 03 Jan 2024 Shandong New Time Pharmaceutical completes a phase II trial in Cervical cancer (Late-stage disease, Recurrent, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in China (IV) (NCT06226350)
- 28 Feb 2023 Shandong New Time Pharmaceutical plans a phase II trial for Non-small cell lung Cancer (NSCLC) (In adults, In the elderly, Late-stage disease, Metastatic disease) in (China) (Intravenous, Infusion) (NCT05741021)
- 13 Feb 2023 Phase-II clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater; Combination therapy) in China (IV) (NCT05740215)